ShavetaVinayakMD

Oncology • Seattle, WA

Instructor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Vinayak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vinayak's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-520-5000

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Virginia Commonwealth University School of MedicineClass of 2004

Certifications & Licensure

CA State Medical License 2007 - Present
WA State Medical License 2018 - 2026
OH State Medical License 2013 - 2019
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

264 citations
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg, Monica M. Mita, Georgia A. McCann
JAMA Oncology. 2019-06-13
50 citations
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers
Yiqing Zhao, Xiujing Feng, Yicheng Chen, J. Eva Selfridge, Shashank Gorityala
Cancer Research. 2020-11-01
234 citations
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine Tung, Mark E. Robson, Steffen Ventz, Cesar A. Santa-Maria, Rita Nanda
Journal of Clinical Oncology. 2020-10-29

Lectures

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. Breast Cancer Immunotherapy: Ca...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Fred Hutch/UW Cancer Consortium Breast Cancer Researchers Receive GrantsNovember 17th, 2022
Research into Targeted Treatments, Better Prediction Models in Breast Cancer FundedNovember 22nd, 2023